An Analysis of Bibliometric Research on Sumatriptan (Imitrex, Tosymra) Linked to Migraine Relief : Sumatriptan and Migraine Relief

Muhammad Umar; Muhammad Osama Malik; Shahid Iqbal; Aqsa Qurban; Aqsa Sadiq; Syeda Safina Zanib; Maham Taimoor Tarar

doi:10.54393/fbt.v3i03.70

Authors

Muhammad Umar Department of Biochemistry, Government College Women University, Faisalabad, Pakistan
Muhammad Osama Malik University of Tulsa, Oklahoma, United States of America
Shahid Iqbal Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
Aqsa Qurban Department of Life Sciences, University of Management and Technology, Lahore, Pakistan
Aqsa Sadiq Doctor of Veterinary and Medicine, Bahauddin Zakariya University, Multan, Pakistan
Syeda Safina Zanib Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
Maham Taimoor Tarar Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

DOI:

https://doi.org/10.54393/fbt.v3i03.70

Keywords:

Sumatriptan, Imitrex, Tosymra, Migraine, Pharmaceutical Research

Abstract

Episodic headaches are a common neurovascular disorder called migraine characterized by a throbbing pain that is typically felt on one side of the brain, however it can occasionally affect both sides. However, no visual bibliometric analysis has been conducted on the effects of sumatriptan on migraine over the past 10 years. Objective: To identify the current status and emerging trends of the global use of sumatriptan associated with the relief of migraine from 2011 to 2022. Methods: Approximately 3154 publications (500 from PubMed and 2654 from dimensions) in CSV format were exported from PubMed and dimensions to VOS viewer. The keywords applied for searching were “sumatriptan” and “sumatriptan in migraine”. Results: The results of bibliometric analysis of the occurrence of keywords by VOS viewer revealed the top four most occurring keywords as “effect”, “relief”, “model”, and “mechanism”. The bibliometric analysis for the graphical distribution of a maximum number of articles by countries in 2011-2022 reveals Germany, the US, and Australia as the top three countries. The analysis for a maximum number of publications by organizations in 2011-2022 showed the top three organizations with a maximum number of articles are “Headache Core Center, Springfield, USA”, “Montefiore Medical Center, USA”, and “Experimental Medicine Research Center, Tehran University”. Conclusions: The compiled data of this exploration will make it easier for other academic research work to find authentic and fruitful results for complex future studies.

References

Pritchard A. Statistical bibliography or bibliometrics. Journal of Documentation. 1969; 25: 348.

Siddique N, Ur Rehman S, Ahmad S, Abbas A, Khan MA. Library and information science research in the Arab World: a bibliometric analysis 1951–2021. Global Knowledge, Memory and Communication. 2023 Jan; 72(1/2): 138-59. doi: 10.1108/GKMC-06-2021-0103.

Mahapatra N and Sahoo J. Metrics employed in the evaluation of research productivity: A systematic literature review. Journal of Librarianship and Information Science. 2023 Sep; 55(3): 868-85. doi: 10.1177/09610006221104798.

Ullah M, Butt IF, Haroon M. The Journal of Ayub Medical College: a 10‐year bibliometric study. Health Information & Libraries Journal. 2008 Jun; 25(2): 116-24. doi: 10.1111/j.1471-1842.2007.00757.x.

Zhou S, Tao Z, Zhu Y, Tao L. Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis. PeerJ. 2019 Nov; 7: e8145. doi: 10.7717/peerj.8145.

Tao L, Zhou S, Tao Z, Wen K, Da W, Meng et al. The publication trends and hot spots of scoliosis research from 2009 to 2018: a 10-year bibliometric analysis. Annals of Translational Medicine. 2020 Mar; 8(6). doi: 10.21037/atm.2020.02.67.

He K, Zhan M, Li X, Wu L, Liang K, Ma R. A bibliometric of trends on acupuncture research about migraine: quantitative and qualitative analyses. Journal of Pain Research. 2022 Apr: 1257-69. doi: 10.2147/JPR.S361652.

Waltman L, Van Eck NJ, Noyons EC. A unified approach to mapping and clustering of bibliometric networks. Journal of Informetrics. 2010 Oct; 4(4): 629-35. doi: 10.1016/j.joi.2010.07.002.

Van Eck NJ and Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017 May; 111: 1053-70. doi: 0.1007/s11192-017-2300-7.

Jensen R and Stovner LJ. Epidemiology and comorbidity of headache. The Lancet Neurology. 2008 Apr; 7(4): 354-61. doi: 10.1016/S1474-4422(08)70062-0.

Diener HC, Kronfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. The Lancet Neurology. 2006 Apr; 5(4): 310-6. doi: 10.1016/S1474-4422(06)70382-9.

Lipton RB, Munjal S, Brand‐Schieber E, Rapoport AM. DFN‐02 (sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: A double‐blind, placebo‐controlled study. Headache: The Journal of Head and Face Pain. 2018 May; 58(5): 676-87. doi: 10.1111/head.13309.

Spindler BL and Ryan M. Medications approved for preventing migraine headaches. The American Journal of Medicine. 2020 Jun; 133(6): 664-7. doi: 10.1016/j.amjmed.2020.01.031.

Wells RE, O’Connell N, Pierce CR, Estave P, Penzien DB, Loder E et al. Effectiveness of mindfulness meditation vs headache education for adults with migraine: a randomized clinical trial. JAMA Internal Medicine. 2021 Mar; 181(3): 317-28. doi: 10.1001/jamainternmed.2020.7090.

Steiner TJ and Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nature Reviews Neurology. 2023 Feb; 19(2): 109-17. doi: 10.1038/s41582-022-00763-1.

Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJ et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb; 163(2): e293-309. doi: 10.1097/j.pain.0000000000002275.

Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018 Nov; 17(11): 954-76. doi: 10.1016/S1474-4422(18)30322-3.

Safiri S, Kolahi AA, Hoy D, Buchbinder R, Mansournia MA, Bettampadi D et al. Global, regional, and national burden of neck pain in the general population, 1990-2017: systematic analysis of the Global Burden of Disease Study 2017. BMJ. 2020 Mar; 368. doi: 10.1136/bmj.m791.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology. 2017 Jun; 16(6): 425-34. doi: 10.1016/S1474-4422(17)30083-2.

Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar; 27(3): 193-210. doi: 10.1111/j.1468-2982.2007.01288.x.

Al-Salama ZT and Scott LJ. Sumatriptan nasal powder: a review in acute treatment of migraine. Drugs. 2016 Oct; 76: 1477-84. doi: 10.1007/s40265-016-0641-9.

Fala L. Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura. American Health and Drug Benefits 2019 Mar; 12.

Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA et al. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP‐825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan. Headache: The Journal of Head and Face Pain. 2017 Jun; 57(6): 862-76. doi: 10.1111/head.13105.

Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000 Nov; 106(5): 989-97. doi: 10.1542/peds.106.5.989.

Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018 Feb; 17(2): 174-82. doi: 10.1016/S1474-4422(17)30435-0.

Djupesland PG, Flint A, Sheldrake CD, Docekal P. Nasal delivery of sumatriptan powder with a novel bi-directional device is highly effective in treating a single migraine attack. Headache. 2008; 48: LB-S70. doi:

Hargreaves RJ and Shepheard SL. Pathophysiology of migraine—new insights. Canadian Journal of Neurological Sciences. 1999 Nov; 26(3): 12-9. doi: 10.1017/S0317167100000147.

Tepper SJ and Johnstone MR. Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine. Medical Devices: Evidence and Research. 2018 May: 147-56. doi: 10.2147/MDER.S130900.

Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Archives of Neurology. 2002 Jul; 59(7): 1084-8. doi: 10.1001/archneur.59.7.1084.

Zhao T, Guo J, Song Y, Chen H, Sun M, Chen et al. A bibliometric analysis of research trends of acupuncture therapy in the treatment of migraine from 2000 to 2020. Journal of Pain Research. 2021 May: 1399-414. doi: 10.2147/JPR.S306594.

Zhao Y and Li WT. Knowledge Mapping of Migraine: A Bibliometric Analysis (2000-2019). Research Square. 2021 Jan. doi: 10.21203/rs.3.rs-142994/v1.